Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Goodwill & Intangibles (2019 - 2025)

Historic Goodwill & Intangibles for BridgeBio Pharma (BBIO) over the last 6 years, with Q3 2025 value amounting to $28.8 million.

  • BridgeBio Pharma's Goodwill & Intangibles rose 1741.08% to $28.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.8 million, marking a year-over-year increase of 1741.08%. This contributed to the annual value of $23.9 million for FY2024, which is 909.23% down from last year.
  • Latest data reveals that BridgeBio Pharma reported Goodwill & Intangibles of $28.8 million as of Q3 2025, which was up 1741.08% from $29.5 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Goodwill & Intangibles ranged from a high of $46.2 million in Q3 2021 and a low of $20.0 million during Q2 2021
  • Its 5-year average for Goodwill & Intangibles is $29.1 million, with a median of $28.0 million in 2023.
  • Within the past 5 years, the most significant YoY rise in BridgeBio Pharma's Goodwill & Intangibles was 4954.0% (2022), while the steepest drop was 3656.39% (2022).
  • BridgeBio Pharma's Goodwill & Intangibles (Quarter) stood at $44.9 million in 2021, then crashed by 36.1% to $28.7 million in 2022, then fell by 8.33% to $26.3 million in 2023, then decreased by 9.09% to $23.9 million in 2024, then grew by 20.35% to $28.8 million in 2025.
  • Its last three reported values are $28.8 million in Q3 2025, $29.5 million for Q2 2025, and $27.8 million during Q1 2025.